drugset / Trial / NCT05845307
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
Phase 0
Withdrawn
M.D. Anderson Cancer Center
National Institutes of Health (NIH) · collabTvardi Therapeutics, Incorporated · collab
NaSingle-groupOpen-labelTreatment
Summary
To learn if TTI-101 can reduce the growth of HPV-negative squamous cell carcinomas of the head and neck when given before standard of care surgery.
Timeline
- Start
- 2025-06-20
- Primary completion
- 2025-11-13
- Completion
- 2025-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C-188-9 | Small molecule | — | Oral |